Blood disorders affect one or more parts of the blood and prevent your blood from doing its job. They can be acute or chronic. Many blood disorders are inherited. Other causes include other diseases, side effects of medicines, and a lack of certain nutrients in your diet.
In 2014, the number of deaths from an acute heart infarct dropped by 7 percent to 5.3 thousand in the Netherlands, nearly 400 fewer than in 2013. This decline is more or less equal to previous years. The most common cause in 2014 was dementia with 12.5 thousand deaths. Death from dementia ranks higher than lung cancer or heart infarcts. Nearly 70 percent of deaths from dementia were female, as indicated by Statistics Netherlands. In 2014, 2.9 thousand men and 2.4 thousand women died from an acute heart infarct, in total 400 fewer than one year previously. These numbers have been declining steadily since the 1970s. Explanations for this decline include better prevention (fewer smokers, more awareness of high cholesterol), better organised health care (Coronary Care Units or CCUs in hospitals) and progress made in related treatments (dotter operations, stents and medicine), thus enabling people to survive an acute heart infarct; these people eventually die from other causes. Over 23 thousand men and close to 20 thousand women in the Netherlands died of cancer in 2014. The most common forms of cancer in men are lung cancer (6,170 deaths), colon cancer (including rectal cancer, 2,677 cases) and prostate cancer (2,539 deaths). In women most cases were lung cancer (4,176), breast cancer (3,014) and colon cancer (including rectal cancer, 2,270).
Depending on the disorder, treatment options can include growth factors to stimulate blood cell production, steroids or other drugs to suppress the immune system, and chemotherapy to destroy abnormal cells. Bleeding disorders like hemophilia may call for blood-component therapies, such as platelet transfusions or clotting factors; diseases that involve clotting might be treated with drugs that inhibit clot formation.
The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.